SCHEMBL7922422

SCHEMBL7922422

CN1CCc2ccc(O)cc2C(c2ccccc2F)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 16/20 0.70
HTR2A P28223 2/20 0.70
DRD5 P21918 6/20 0.54
THPO P40225 2/20 0.51
HSD17B10 Q99714 2/20 0.51
MAPK1 P28482 1/20 0.51
HIF1A Q16665 1/20 0.51
MTOR P42345 1/20 0.51
DRD2 P14416 4/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
DRD3 P35462 2/20 0.48
DRD4 P21917 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7919382 0.86 DRD1 (0.72) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL7919553 0.84 DRD1 (0.66) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL8085146 0.83 DRD1 (1.00) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL9838068 0.83 DRD1 (1.00) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL7919616 0.81 DRD1 (0.77) DRD1DRD5THPOHSD17B10DRD2
SCHEMBL7213025 0.77 DRD1 (0.60) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL7922430 0.77 DRD1 (0.55) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL16508939 0.75 DRD1 (0.76) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL7919555 0.75 DRD1 (0.71) DRD1HTR2ADRD5THPOHSD17B10
SCHEMBL8184939 0.75 DRD1 (0.70) DRD1HTR2ADRD5THPOHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6211173-B1 Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders CENES LIMITED (GB) 2001-04-03 US disclosed
EP-1011679-A1 USE OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SLEEP DISORDERS CeNes Limited (GB) 2000-06-28 EP disclosed
WO-1998040072-A1 USE OF 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SLEEP DISORDERS CENES LIMITED (GB) 1998-09-17 WO disclosed
EP-0347672-B1 Benzazepine derivatives NOVO NORDISK AS (DK) 1994-03-02 EP disclosed
US-5025009-A Treatment of central nervous system disorders; bioavailability NOVO NORDISK A/S (DK) 1991-06-18 US disclosed
US-5010074-A Treating CNS disorders; dopamine antagonist; bioavailability NOVO NORDISK A/S (DK) 1991-04-23 US disclosed
EP-0347672-A1 Benzazepine derivatives NOVO NORDISK A/S (DK) 1989-12-27 EP disclosed